Vir Biotechnology Revenue and Competitors
Estimated Revenue & Valuation
- Vir Biotechnology's estimated annual revenue is currently $284.4M per year.
- Vir Biotechnology received $66.0M in venture funding in August 2018.
- Vir Biotechnology's estimated revenue per employee is $393,361
- Vir Biotechnology's total funding is $793.6M.
- Vir Biotechnology's current valuation is $5.1B. (January 2022)
Employee Data
- Vir Biotechnology has 723 Employees.
- Vir Biotechnology grew their employee count by -7% last year.
Vir Biotechnology's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP and Chief Staff, Office the CMO, Vir Biotechnology | Reveal Email/Phone |
2 | SVP, Chief Information Officer | Reveal Email/Phone |
3 | EVP, Regulatory and Program Leadership | Reveal Email/Phone |
4 | SVP, Regulatory Affairs | Reveal Email/Phone |
5 | Head Procurement | Reveal Email/Phone |
6 | VP, Development Business Operations | Reveal Email/Phone |
7 | VP, Bioprocess Development | Reveal Email/Phone |
8 | VP, Head Operations Finance | Reveal Email/Phone |
9 | Head Policy and Government Affairs | Reveal Email/Phone |
10 | SVP, Clinical Research, Head Chronic Infection | Reveal Email/Phone |
Vir Biotechnology Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Vir Biotechnology?
Vir brings together cutting-edge innovations with leading scientific expertise and management to take on some of the world's most challenging infectious diseases for which solutions are non-existent or inadequate. Vir seeks to take a new approach, using breakthroughs in immune programming to manipulate pathogen-host interactions. The company will take a multi-program, multi-platform approach to applying these breakthroughs, guided by rigorous science and driven by medical need.
keywords:Biotechnology
$793.6M
Total Funding
723
Number of Employees
$284.4M
Revenue (est)
-7%
Employee Growth %
$5.1B
Valuation
N/A
Accelerator
Vir Biotechnology News
Vir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and...
Shares of Vir Biotechnology ( VIR -2.05% ) were up 20.5% so far for ... of an announcement on March 25 that drove Vir's stock price down.
Shares of Vir Biotechnology ( VIR -4.32% ) were skyrocketing 19.4% higher as of 12:33 p.m. ET on Wednesday. The big jump came after S&P...
GlaxoSmithKline and Vir Biotechnology, Inc. announced they have an agreement to enter a partnership to research and develop solutions for coronaviruses. And GSK will be investing $250 million in Vir. GlaxoSmithKline plc (GSK) and Vir Biotechnology, Inc. announced they have signed a binding agre ...
Vir’s shares were up 11% on the Nasdaq in mid-day trading Thursday following the news. Biogen has been hit hard by an outbreak of the coronavirus following a management meeting in Boston two weeks ago. Shortly after the meeting, the company disclosed that three employees who attended had tested ...
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $273.7M | 724 | N/A | N/A |
#2 | $147.2M | 725 | -3% | N/A |
#3 | $328.3M | 726 | 8% | N/A |
#4 | $15M | 726 | N/A | N/A |
#5 | $274.4M | 726 | 11% | N/A |
Vir Biotechnology Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2018-08-10 | $66.0M | Undisclosed | Article |